News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients
Oct 9, 2024, 07:16

Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients

Diego Prost, Medical oncologist and Neuro-oncology fellow at Pitié-Salpêtrière University Hospital, shared a post on X:

”Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review – ESMO Open.

Better outcomes are associated with histology, treatment response, and targeted therapy.

Proud to collaborate with Hospital Saint-Joseph and The National Cancer Institute of Milan.”

Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review

Authors: D. Prost, S. Iseas, M. Gatineau, J. Adam, S. Cavalieri, C. Bergamini, L. Licitra, É. Raymond.

Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients

Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients

Source: Diego Prost/X

C. Bergamini cancer D. Prost Diego Prost É. Raymond ESMO Open Histology Hospital Saint-Joseph J. Adam L. Licitra M. Gatineau OncoDaily Oncology S. Cavalieri S. Iseas Salivary Gland Cancer targeted therapy The National Cancer Institute of Milan treatment response
Special Coverage
Insight
Nov 13, 2024, 11:10
Myeloma Paper of the Day, November 13th, suggested by Robert Orlowski
Blog
Nov 13, 2024, 11:01
LGCW2024 session on Galvanising African cancer research building a strong cancer workforce - AORTIC- Africa
Blog
Nov 13, 2024, 10:59
Bernard Fox received SITC lifetime achievement award
Blog
Nov 13, 2024, 10:54
Hear Her campaign Increasing awareness about lung cancer in women
Blog
Nov 13, 2024, 10:52
Johnson & Johnson Seeks Approval for DARZALEX FASPRO as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma
Blog
Nov 13, 2024, 10:47
FDA approves obecabtagene autoleucel for relapsed or refractory B-cell precursor ALL
Blog
Nov 13, 2024, 10:45
OncoInfluencers to Follow on Social Media: Dr. Nitin Jain
Insight
Nov 13, 2024, 10:37
UCLA: Combination approach shows promise for treating rare, aggressive cancers
Opinion
Nov 13, 2024, 10:32
The 6th Biennial Miami Epigenetics and Cancer Symposium to be held in Sylvester Comprehensive Cancer Center
Blog
Nov 13, 2024, 10:16
Highlights from IU Simon Comprehensive Cancer Center’s End Lung Cancer Now Gathering - Hoosier Cancer Research Network
Blog
Nov 13, 2024, 10:06
A first-in-class Antibody Drug Conjugate that works by directly stimulating the immune system
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program